No abstract

Anti-Echinococcus serum immunoglobulin (Ig)E was assessed by the ImmunoCAP system and compared with anti-Echinococcus serum IgG assessed by enzyme-linked immunosorbent assay (ELISA) and Western blot. The ImmunoCAP system revealed very high specificity (one false positive of 110 healthy individuals), low cross-reactivity (one false positive of 58 patients with other diseases) and decreased sensitivity (73.55%). Receiver operating characteristic analysis displayed a beneficial diagnostic value with high accuracy. Comparison of the ImmunoCAP system with ELISA and Western blot showed significantly higher specificity and significantly lower cross-reactivity compared with the ELISA. Examination of sera from 155 patients with cystic echinococcosis (CE) showed varying levels of anti-Echinococcus IgE (range, 0.01-118.33 kUA/L). However, most samples had moderately elevated IgE levels. Analysis of serum-specific IgE revealed significantly higher sensitivity of the ImmunoCAP system and significantly higher antibody levels in hepatic CE compared with pulmonary CE.

The successful use of the Bulgarian grass pollen allergen B1 and both flow cytometry tests was presented. These methods could be as specific tools for IgE-mediated diagnosis especially FastImmune in the case of low IgE receptor expression.

(1) Background: Biomarkers of efficacy for subcutaneous immunotherapy (SCIT) on allergic rhinitis have not been evaluated in details. The present study aims to assess the relevance of measuring of sIgE, sIgG4 and IgE/IgG4 ratio during SCIT in patients with allergic rhinitis; (2) Methods: 20 patients, 13 men and 7 women aged 19 to 58 years, with clinically manifested seasonal and perennial allergic rhinitis were studied. At the initiation and in the end of the three-year course of SCIT serum allergen-specific IgE and IgG4 were measured with ImmunoCAP system. The sIgE/sIgG4 ratio was calculated as a biomarker for immunologic effectiveness; (3) Results: There was a significant increase of sIgG4 antibodies (p < 0.05), while at the end of SCIT for the sIgE levels no significant changes were seen (p > 0.05). Moreover, 90% of patients showed a decrease of the IgE/IgG4 ratio; (4) Conclusions: In most of treated patients with AR, SCIT with Bulgarian allergen products leads to clear immunological changes. After a 3-year of SCIT there is a significant increase in allergen specific IgG4 levels and both decrease of sIgE and IgE/IgG4 ratio. sIgE, sIgG4 and IgE/IgG4 ratio can be used as a substantial biomarker for predicting immunological effectiveness of SCIT.

Data in the literature addressing the ability of Toxocara infection in humans to induce development of atopic disease are controversial. The aim of our study was to determine the seroprevalence of anti-Toxocara antibodies in three groups of people: subjects with allergic symptoms and presence of allergen-specific IgE, subjects with allergic symptoms and absence of allergen-specific IgE, and clinically healthy blood donors. Serum samples from all subjects were tested by ELISA and Western blot for presence of specific antibodies against Toxocara canis. The results of our study did not support the link between toxocariasis and allergic manifestations in atopic patients. Among subjects with allergic symptoms and absence of atopy was found seroprevalence of 2·2% in Western blot. Same index in patients with atopy was 0·8%, and in clinically healthy blood donors 4·0%. Our study gives us grounds to consider that it is appropriate persons with allergic reactions, without evidence of atopy to be tested for presence of anti-Toxocara antibodies in the course of their diagnostic evaluation. Data from clinically healthy persons suggest that there is a 'hidden' infection among the population, which is not clinically manifested.

MX1 (N-[3-(3-(1-piperidinylmethyl)phenoxy)propyl]-hydroxyacetamide+ ++ 2-hydroxypropane-1,2,3-tricarboxylate bismuth (3+) complex) is a novel salt of the active metabolite of H2-antagonist roxatidine with a complex of bismuth with citric acid. In a model of ethanol-induced ulcers in male Wistar rats, both roxatidine and the bismuth salt reduced the number and the total length of lesions. Comparison of roxatidine and MX1 at equimolar doses of 160 mumol kg-1 showed a more potent cytoprotective effect of MX1. The potency of anti-secretory and antiacidic effects of MX1 was more than twice that of roxatidine on histamine-stimulated secretion in female Wistar pylorus-ligated rats. Microbiological tests with the reference bismuth preparation De-Nol showed prominent anti-Helicobacter properties of MX1 in-vitro. Both test compounds had similar range of MICs to Helicobacter pylori, from 4 to 64 microgram bismuth mL-1. The cytoprotective, antisecretory, anti-acidic and anti-Helicobacter properties of the new agent MX1 warrant further more extensive pharmacological and clinical trials.

Purpose: Platanus pollen is a serious cause of asthma, allergic rhinitis and conjunctivitis in many European countries. The aim of the present pilot study is to investigate the sensitization to 3 different plane tree species in a group of patients with pollinosis. Materials and methods: 21 patients were surveyed - 11 men and 10 women. A skin prick test was performed with a set of allergens: Grass pollen mix; Betulaceae pollen mix; Platanusorientalis; Platanusacerifolia; Platanusoccidentalis. Results: 95% of patients are sensitized to grass pollen, with moderate positive skin reactions predominating. 86% have a co-sensitization to tree pollens also, particularly to the birch tree family. Only 3 (14%) of the studied patients showed slight positive skin tests to the studied plane tree allergens, with no significant difference in sensitization to studied Platanus species (p>0,05). Conclusion: At present, the sensitization to different Platanus species is not comparable to that of grass or birch pollen. However, it will be necessary to conduct new long-term, large-scale studies to prove whether Platanus pose a real threat to people in urban areas. The results of this interdisciplinary study are important both for clinical allergologists and for landscape architects and ecologists involved in the planning and management of urban green infrastructure.

No abstract